Pacemaker technologies have advanced dramatically over the decades since they were first introduced, and every year many thousands of new implants are performed worldwide. However, there continues to be a high incidence of acute and chronic complications, most of which are linked to the lead or the surgical pocket created to hold the device. A leadless pacemaker offers the possibility of bypassing these complications, but requires a catheter-based delivery system and a means of retrieval at the end of the device's life, as well as a way of repositioning to achieve satisfactory pacing thresholds and R waves, a communication system and low peak energy requirements. A completely self-contained leadless pacemaker has recently been developed, and its key characteristics are discussed, along with the results of an efficacy and safety trial in an animal model. The results of the LEADLESS study, the first human trial to look at safety and feasibility of the leadless device, are discussed and the possible implications for future clinical practice examined.

Chairman Department of Cardiology Homolka Hospital Prague Czech Republic

Director Department of Cardiology Kerckhoff Heart Centre Bad Nauheim Germany

Electrophysiologist Academic Medical Centre University of Amsterdam The Netherlands

Medical Writer Radcliffe Cardiology

See more in PubMed

Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009--a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol. 2011;34:1013–27. PubMed

van Eck JW, van Hemel NM, Zuithof P et al. Incidence and predictors of in-hospital events after first implantation of pacemakers. Europace. 2007;9:884–9. PubMed

Udo EO, Zuithoff N, van Hemel NM et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm. 2012;9:728–35. PubMed

Wiegand UK, LeJeune D, Boguschewski F et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest. 2004;126:1177–86. PubMed

Przybylski A, Derejko P, Kwasniewski W et al. Bleeding complications after pacemaker or cardioverter-defibrillator implantation in patients receiving dual antiplatelet therapy: Results of a prospective, two-centre registry. Neth Heart J. 2010;18:230–5. PubMed PMC

Klug D, Balde M, Pavin D et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study, Circulation. 2007;116:1349–55. PubMed

Medtronic. Cardiac Rhythm Disease Management Product Performance Report 2013 First Edition –Issue 68. Available at: wwwp.medtronic.com/productperformance-files/ Issue%2068%20MDT%20CRDM%20PPR%202013%201st%20 Edition.pdf (accessed 1 April 2014).

St Jude Medical Implantable Electronic Systems Division. Product Performance Report First Edition 2013

Boston Scientific CRM Product Performance Report 2013 Q3 Edition. Available at: www.bostonscientific-international.com/templatedata/imports/HTML/PPR/ppr/references/report_download_2013_q3.shtml. (accessed 1 April 2014)

Kirkfeldt RE, Johansen JB, Nohr EA et al. Risk factors for lead complications in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Heart Rhythm. 2011;8:1622–8. PubMed

van Rees JB, de Bie MK, Thijssen J et al. Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials. J Am Coll Cardiol. 2011;58:995–1000. PubMed

Banaszewski M, Stepinska J. Right heart perforation by pacemaker leads. Arch Med Sci. 2012;8:11–3. PubMed PMC

Howell C, Bergin JD. A case report of pacemaker lead perforation causing late pericardial effusion and subacute cardiac tamponade. J Cardiovasc Nurs. 2005;20:271–5. PubMed

Bracke F, Meijer A, van Gelder LM. Pacemaker lead complications: when is extraction appropriate and what can we learn from published data? Heart. 2001;85:254–9. PubMed PMC

Buch E, Boyle NG, Belott PH. Pacemaker and defibrillator lead extraction. Circulation. 2011;123:e378–80. PubMed

Maytin M, Epstein LM, Henrikson CA. Lead extraction is preferred for lead revisions and system upgrades: when less is more. Circ Arrhythm Electrophysiol. 2010;3:413–24. PubMed

Spickler JW, Rasor NS, Kezdi P et al. Totally self-contained intracardiac pacemaker. J Electrocardiol. 1970;3:325–31. PubMed

Sperzel J, Khairkhahan A, Ligon D, Zaltsberg S. Feasibility, efficacy and safety of percutaneous retrieval of a leadless cardiac pacemaker in an in vivo ovine model. Abstract 859. Europace. 2013;15(suppl 2):ii112–3.

Reddy V Percutaneous In Vivo Placement Of A Novel Intracardiac Leadless Pacemaker: Results From The First-in-man Leadless Study (SP22, Presentation LB02-01). Presented at: Heart Rhythm Society Meeting, Denver, CO, US, 8–11 May 2013

Barakat K, Robinson NM, Spurrell RA. Transvenous pacing lead-induced thrombosis: a series of cases with a review of the literature. Cardiology. 2000;93:142–8. PubMed

Reddy VY, Knops RE, Sperzel J et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation. 2014. ePub ahead of print. PubMed